成人Fontan患者心脏移植:FALD超越传统预测因素的新见解
既往开胸>4次、围术期大出血和肝脏体积小与90天死亡率增加相关,客观肝脏指标或可辅助风险分层但需外部验证。
要点
- 既往开胸>4次、围术期大出血和小肝脏体积与Fontan患者孤立心脏移植后90天死亡率增加相关。
- 肝脏指标TLV≤1366 mL、TLVi<786 mL/m2、LTD<21 cm或可辅助风险分层,但属探索性。
- 心肝联合移植是可行选择,但非肝脏相关移植风险因素同样影响结局。
核心结论
- 在成人Fontan患者孤立心脏移植中,既往开胸>4次、围术期大出血和小肝脏体积与90天死亡率增加相关。
- 客观肝脏指标(TLV≤1366 mL、TLVi<786 mL/m2、LTD<21 cm)可能提供辅助风险分层,但属探索性且需外部验证。
- 心肝联合移植是可行选择,但非肝脏相关移植风险因素可能同样影响结局。
研究设计与样本
- 采用单因素分析和惩罚多变量逻辑回归评估90天死亡相关因素,并用ROC分析推导肝脏尺寸截断值。
- 另对5例接受心肝联合移植的成人Fontan患者进行描述性分析以作背景比较。
主要发现
- 与90天死亡率增加相关的因素包括既往开胸>4次、围术期大出血和小肝脏体积(TLV≤1366 mL、TLVi<786 mL/m2、LTD<21 cm)。
- 多发胸腔静脉-静脉侧支、既往开胸>4次和小肝脏与出血及后续致命并发症(包括脓毒症、移植物功能障碍和肠缺血)强烈相关。
- 5例心肝联合移植患者均有活检证实的晚期肝病,伴临床显著门脉高压特征或肝细胞癌;其中1例在90天内死于多器官衰竭。
关键数值与推荐
- 小肝脏体积截断值:TLV≤1366 mL、TLVi<786 mL/m2、LTD<21 cm。
- 心肝联合移植组5例中1例90天内死亡。
临床怎么用
- 对考虑孤立心脏移植的成人Fontan患者,应评估既往开胸次数、围术期出血风险及肝脏体积指标以辅助风险分层。
- 肝脏指标截断值目前仅为探索性,不能作为独立决策依据,需外部验证。
- 建议在有经验的高容量先天性心脏病移植中心进行详细肝脏评估和管理。
局限性
- 肝脏指标截断值及所提阈值属探索性,需外部验证。
- 心肝联合移植仅作描述性分析,样本极少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fontan patients are considered high risk for heart transplantation (HT) owing to their complex anatomy, multiple prior chest entries, and universal Fontan-associated liver disease (FALD). The impact of FALD and other preoperative factors remains, however, uncertain. OBJECTIVES: We sought to identify factors associated with 90-day mortality after isolated HT in adults with Fontan circulation, with particular focus on the relationship between liver-related parameters and post-transplant outcomes. METHODS: A retrospective cohort study of all adult Fontan patients undergoing isolated HT was conducted. Factors associated with 90-day mortality were assessed using appropriate univariate analyses and penalized multivariable logistic regression. ROC analysis was used to derive liver size cut-offs and compare the discriminative performance of selected variables. A descriptive analysis of adult Fontan patients undergoing combined heart-liver transplantation (CHLT) was also performed for contextual comparison. RESULTS: Thirty-seven patients (mean age 30 years) underwent isolated HT; 19% (n=8) died within 90 days. Factors associated with increased 90-day mortality were >4 previous chest entries, major perioperative bleeding, and small liver size [total liver volume (TLV) ≤1366 mL, total liver volume indexed to body surface area (TLVi) <786 mL/m2 and liver transverse dimension (LTD) <21 cm]. Multiple chest veno-venous collaterals, >4 previous chest entries, and small liver were strongly associated with bleeding and subsequent fatal complications including sepsis, graft dysfunction, and bowel ischaemia. Within the study period, five other patients had undergone CHLT. All had biopsy confirmed advanced liver disease with features of clinically significant portal hypertension or hepatocellular carcinoma. One patient died within 90 days following prolonged cardiopulmonary bypass, major bleeding, graft dysfunction and sepsis, culminating in multiorgan failure. CONCLUSIONS: In Fontan patients undergoing isolated HT, >4 previous chest entries, major bleeding, and small liver volume were associated with increased 90-day mortality. Objective liver metrics (TLV ≤1366 mL, TLVi <786 mL/m2, TLD <21 cm) may provide adjunctive risk stratification for Fontan patients considered for isolated HT; however, these measures and proposed thresholds remain exploratory and require external validation. CHLT is a viable option, although non-liver related transplant risk factors may similarly influence outcomes. Detailed liver assessment and management at experienced, high-volume congenital transplant centres are important to optimizing outcomes in this complex population.
引用
- Rybicka J, Coats L, Crossland D, et al. Heart Transplantation in Adult Fontan Patients: New Insights from Fontan-Associated Liver Disease Beyond Traditional Predictors. J Heart Lung Transplant. 2026. PMID: 42896765. doi:10.1016/j.healun.2026.10.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。